Welcome to our dedicated page for Geovax Labs news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
News linked to the GOVXW symbol centers on GeoVax Labs, Inc., a clinical-stage biotechnology company whose common stock trades as GOVX on Nasdaq. Company announcements describe active development of vaccines and immunotherapies for infectious diseases and solid tumor cancers, providing context for investors tracking the performance and milestones associated with GeoVax-related warrants.
GeoVax’s news flow frequently highlights progress in its lead COVID-19 vaccine program, GEO-CM04S1, including updates on Phase 2 clinical trials and preparations for a BARDA-supported Phase 2b efficacy study. Releases also cover interim data reviews, such as immune response outcomes in patients with chronic lymphocytic leukemia, and broader plans for evaluating GEO-CM04S1 in immunocompromised and healthy populations.
Oncology developments form another key theme in the company’s news. GeoVax reports on its oncolytic solid tumor gene-directed therapy Gedeptin, including completion of a multicenter Phase 1/2 trial for advanced head and neck cancers and plans for a Phase 2 trial in first recurrent head and neck cancer in combination with an immune checkpoint inhibitor. Additional updates describe patent allowances and preclinical data for MVA-VLP-MUC1 and other tumor-associated antigen programs.
Investors following GOVXW-related activity can also expect news on GeoVax’s Mpox and Smallpox vaccine candidate GEO-MVA, corporate and financing transactions, conference presentations, and regulatory filings. Together, these items provide insight into clinical progress, capital strategy, and regulatory interactions that may be relevant when assessing the underlying company to which the GOVXW warrants are tied.
GeoVax Labs announces the filing of two key patent applications focused on vaccines for SARS-CoV-2 and cancer immunotherapies. The International Patent Application under the Patent Cooperation Treaty aims to protect their COVID-19 vaccines, which target multiple viral antigens, potentially reducing susceptibility to mutations. Additionally, a U.S. patent application was filed to enhance immune responses to cancer through its modified vaccinia Ankara viral vector technology. The company now has over 70 patent applications and is advancing towards clinical development in both areas.
GeoVax Labs, Inc. (NasdaqCM: GOVX) will participate in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Chairman and CEO David Dodd is set to present, with an on-demand listening option starting at 7:00 AM ET on March 9. The presentation will be available for 90 days. Investors can schedule virtual one-on-one meetings with Mr. Dodd during the conference. GeoVax is focused on developing vaccines for infectious diseases and cancer, including COVID-19 and HIV, utilizing an innovative vaccine platform.
GeoVax Labs, Inc. (NasdaqCM: GOVX) announced that CEO David Dodd and CFO Mark Reynolds will deliver a presentation titled “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” at a Tribe Public webinar on March 3, 2021, at 8:30 AM Pacific/11:30 AM Eastern. The event aims to engage audiences regarding their innovative vaccine technologies against infectious diseases and cancer. Interested participants can register for the complimentary ZOOM webinar.
GeoVax Labs, Inc. (GOVX) announced the successful closing of a bought deal offering, selling 1,644,000 shares at $6.25 each, resulting in gross proceeds of approximately $10.3 million. The offering included 204,000 shares from an underwriter's full exercise of additional shares option. Maxim Group LLC acted as the sole book-running manager for the offering. This initiative was conducted under a registration statement filed with the SEC. GeoVax is focused on developing vaccines for various infectious diseases and cancer, utilizing its patented MVA-VLP platform.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced an underwriting agreement with Maxim Group LLC to sell 1,440,000 shares of common stock at $6.25 per share, aiming for gross proceeds of approximately $9.0 million before expenses. The underwriters also have an option to purchase an additional 204,000 shares. The offering is expected to close on February 11, 2021, pending customary conditions. Shares are being offered under a shelf registration statement previously approved by the SEC.
GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) has closed its public offering, raising $12.8 million by issuing 2,560,000 units of common stock, pre-funded warrants, and warrants. Each unit consists of one share of common stock and a five-year warrant at an exercise price of $5.00. The offering included 2,310,000 units priced at $5.00 per unit and 250,000 units at $4.99. The company granted underwriters a 45-day option for an additional 384,000 shares to cover over-allotments.
GeoVax Labs, Inc. (NasdaqCM: GOVX, GOVXW) announced a public offering of 2,560,000 units priced at $5.00 each, expected to yield $12.8 million before expenses. The offering includes common stock and warrants, starting trading on September 25, 2020. Concurrently, a 1-for-20 reverse stock split will take effect. The closing is anticipated on September 29, 2020, pending customary conditions. An additional 384,000 units may be purchased by underwriters within 45 days to cover over-allotments.